Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects
oleh: Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer, Peter K. Sorger
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-02-01 |
Deskripsi
Analysis of more than 150 Phase 3 oncology clinical trials supports parametric statistical analysis, significantly increasing the precision of small early-phase trials and relating deviations from the Cox proportional hazards model to trial duration.